We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...

A Maryland drug affordability board can move forward with a plan to cap how much the state and local governments pay for ...

Molecular Partners (MOLN) and Orano Med announced the oral presentation of the latest preclinical data supporting MP0712 as a Radio-DARPin ...

Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction. If you don't have a login or your access has expired, you will need to ...

The Philippine Press Institute (PPI) together with Novartis held a hybrid seminar-workshop for journalists entitled “Anatomy ...

The global congenital hyperinsulinism treatment market is set to reach USD 100 million by 2023 and is expected to grow at a ...

The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...

The growth of the Myotonic Dystrophy Treatment Market is being fueled by strategic initiatives adopted by leading ...

The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson reported strong ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...